Topic of the Month on ModernWeight: Redefining Weight Management Together: Let's Talk Stigma and Solutions
Head to the Social Hub to share your success story or learn about others.
AOMs in the News
This Week's Featured Post
Policy Support for GLP-1 Can Combat Chronic Diseases
Link: U.S. Chamber of Commerce
This week's featured article explores how policy support can unlock the potential of GLP-1 medications to address chronic diseases like obesity and Type 2 diabetes. These medications have revolutionized treatment, but for their full potential to be realized, policymakers must back innovation and access to ensure that all patients benefit. Without the right policies, progress could stall, putting the health of millions of Americans at risk.
The author, from the U.S. Chamber of Commerce, underscores the urgent need for supportive policy measures that foster innovation, accessibility, and affordability for GLP-1 drugs. They argue that the healthcare and economic burden of chronic diseases will only grow if we fail to prioritize these medications. Innovative policy is the key to maximizing the impact of GLP-1 drugs on national healthcare outcomes.
Why it matters: GLP-1 medications like Ozempic and Wegovy have already revolutionized obesity treatment, and their impact on chronic conditions such as heart disease and Type 2 diabetes is growing. With chronic diseases being the leading cause of death in the U.S., policy measures that support GLP-1 innovation and accessibility are essential for reducing healthcare costs and improving public health outcomes.
Four Key Factors Affecting Weight Loss on GLP-1 Drugs
Link: Healthline
New research from the Cleveland Clinic identifies four critical factors that affect how much weight people lose on GLP-1 drugs like Ozempic and Wegovy. The four factors are as follows: medication type, dosage, treatment indication, and how long patients stick to the medication. The study emphasizes that long-term success depends on these factors, alongside patient persistence.
Why it matters: This study is important because it outlines the keys to maximizing weight loss results for patients on GLP-1 medications. While these drugs are powerful, access and cost remain barriers for many, making it crucial to understand how different factors influence outcomes.
GLP-1 Drugs Could Prevent 34,000 Heart Attacks and Strokes Annually
Link: CNN
According to new research, GLP-1 drugs could prevent an estimated 34,000 heart attacks and strokes in the U.S. each year. These findings build on earlier data that showed cardiovascular benefits for people with obesity or Type 2 diabetes taking Wegovy. The study suggests that the benefits of GLP-1 drugs could extend beyond their current patient base, offering hope for even more significant reductions in heart disease risks.
Why it matters: Heart disease remains the number one killer in the U.S. Expanding the use of GLP-1 drugs could have profound implications for public health by reducing the burden of cardiovascular events, improving overall life expectancy, and lowering healthcare costs related to heart disease treatment.
Mounjaro, Wegovy, and Rybelsus – What We Know So Far
Link: Diabetes Care
GLP-1/GIP analogs like Mounjaro, Wegovy, and Rybelsus are showing promising results in treating both Type 2 diabetes and obesity. These medications work by addressing the multifactorial nature of these diseases, offering a comprehensive approach that includes weight management and blood sugar control. However, researchers emphasize the need for continuous use to maintain benefits.
Why it matters: The growing prevalence of Type 2 diabetes and obesity highlights the urgent need for effective treatments. These new GLP-1/GIP analogs provide hope for improved long-term outcomes, but their cost and access remain concerns for many patients.
GLP-1 RAs Improve Asthma Control in Obese Patients
Link: Healio
A study presented at the European Respiratory Society International Congress found that obese patients with asthma who took GLP-1 receptor agonists experienced better asthma control compared to those who did not. The findings suggest that GLP-1 medications, though primarily for weight loss and diabetes, may have additional benefits for respiratory conditions like asthma.
Why it matters: This research adds to the growing body of evidence that GLP-1 medications can offer far-reaching health benefits beyond just weight loss and diabetes management. For patients with obesity and asthma, these findings may lead to better overall treatment outcomes and quality of life.
---
Expert Tweet of the Week
From @CaulfieldTim
“Are We Thinking About #Obesity All Wrong?
@BevTchangMD: “The problem is that we’ve allowed society, insurance companies and everyone else to decide that obesity is just too much fat, which is an oversimplification.”
by (the always great)
@juliaoftoronto
---
Our ModernWeight "Weekly Weight Management Insights" newsletter is designed to keep you informed and engaged with the latest in weight management and GLP-1 medications. Visit the Social Hub to join the conversation and connect with our community.
Want to receive this newsletter in your inbox weekly? Create a profile!
Comments